Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Prospective clinical study on the efficacy and safety of the DCIA±X regimen in treating relapsed/refractory acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYi Zhun ZhuXTXiwen TongBXBin Xu

Discussion

Loading...

Member takes

Overview

Prospective study shows 81.8% complete remission in relapsed acute myeloid leukemia, indicating effective cancer treatment.

Key Points

  • To evaluate the efficacy and safety of the DCIA±X regimen for treating relapsed/refractory acute myeloid leukemia.
  • Single-arm prospective study
  • Conducted at Tongji Hospital, Huazhong University
  • Patients aged 18-60 with R/R AML
  • Received DCIA±X regimen
  • Data analyzed using SPSS (version 27)
  • 81.8% achieved complete remission/complete remission with incomplete recovery
  • 95.4% overall response rate
  • 63.6% proceeded to allogeneic transplantation
  • 1-year relapse-free survival at 68.5%
  • 1-year overall survival at 84.78%

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d372https://doi.org/10.1182/blood-2025-6989
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ruxolitinib combined with decitabine-intensified modified busulfan/cyclophosphamide conditioning regimen reduces relapse after allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia2025
  2. 2Mega‐dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory <scp>AML</scp> with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase <scp>II</scp> study2024 · 2 citations
  3. 3Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy2026
  4. 4Role of Maintenance Therapy with Decitabine in Acute Myeloid Leukemia in First Remission: A Prospective Interventional Study from a Tertiary Care Center in Eastern India2025
  5. 5Chidamide combined with decitabine, venetoclax, and low-dose cytarabine for relapsed/refractory acute myeloid leukemia: a single-center case series2026 · 1 citations